What guidance did Precigen's management provide for the next earnings period?

Did Precigen beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for Precigen year over year?

What is the market's earnings forecast for Precigen next quarter?

What is Precigen's gross profit margin?

What is Precigen's latest dividend and current dividend yield?

What were the key takeaways from Precigen’s earnings call?

What were the key takeaways from Precigen's earnings call?

- **Breakthrough Therapy Launched**: PAPZIMEOS approved for all adult RRP patients with 51% complete response rate and 3+ years surgery-free durability.
- **Commercial Momentum**: 90% of target institutions engaged, 80M+ lives covered, $123.6M cash to fund 2026 breakeven.
- **Growth Catalysts**: European expansion underway, pediatric trials planned, redosing supported by clinical data.
- **Financial Discipline**: 15-20% gross margin, non-cash losses resolved, no recurring dilution.

**【CEO Summary Section】**
- PAPZIMEOS received FDA approval for all adult RRP patients, driven by 51% complete response rate and 86% reduction in surgeries.
- 15-year development timeline resulted in unmatched durability (3+ years without surgery) and safety profile comparable to flu vaccines.
- EMA submission underway for European expansion, with pediatric trials planned.

**【CFO Financial Commentary】**
- $123.6M cash on hand, with projected cash flow breakeven by end-2026.
- Q3 2025 net loss of $1.06M (non-cash items: $0.95M deemed dividend/warrant liability).
- Gross-to-net revenue adjustment expected at 15-20%, consistent with biotech peers.

**【Q&A Highlights】**
- 90% of target institutions engaged, 100+ patients registered in launch hub.
- Payer coverage exceeds 80M lives, including Medicare/Medicaid.
- Revenue recognized upon shipment, not injection.
- Redosing potential supported by durability data and physician discretion.
- Strong demand from both academic centers and community practices.


PGEN

PGEN fundamentals

You can ask Aime